Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018, Article ID 4573452, 9 pages
https://doi.org/10.1155/2018/4573452
Research Article

Which Kidney Transplant Recipients Can Benefit from the Initial Tacrolimus Dose Reduction?

1Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland
2Department of Pathophysiology, Medical University of Silesia, Katowice, Poland
3Department of Internal Diseases and Oncological Chemotherapy, Medical University of Silesia, Katowice, Poland

Correspondence should be addressed to Aureliusz Kolonko; lp.pw@zsuinyru

Received 18 July 2017; Accepted 1 January 2018; Published 30 January 2018

Academic Editor: Takahisa Gono

Copyright © 2018 Kinga Krzyżowska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Schiff, E. Cole, and M. Cantarovich, “Therapeutic monitoring of calcineurin inhibitors for the nephrologist,” Clinical Journal of the American Society of Nephrology, vol. 2, no. 2, pp. 374–384, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Saint-Marcoux, J.-B. Woillard, C. Jurado, and P. Marquet, “Lessons from routine dose adjustment of tacrolimus in renal transplant patients based on global exposure,” Therapeutic Drug Monitoring, vol. 35, no. 3, pp. 322–327, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. C. E. Staatz and S. E. Tett, “Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation,” Clinical Pharmacokinetics, vol. 43, no. 10, pp. 623–653, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Rehman, X. Wen, M. J. Casey, A. H. Santos, and K. Andreoni, “Effect of different tacrolimus levels on early outcomes after kidney transplantation,” Annals of Transplantation, vol. 19, no. 1, pp. 68–75, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Rodrigo, C. Piñera, M. A. De Cos et al., “Evolution of tacrolimus blood levels and concentration-dose ratios in patients who develop new onset diabetes mellitus after kidney transplantation,” Transplant International, vol. 18, no. 10, pp. 1152–1157, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. J. J. G. De Lima, H. Xue, L. Coburn et al., “Effects of FK506 in rat and human resistance arteries,” Kidney International, vol. 55, no. 4, pp. 1518–1527, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. R. A. Caires, I. D. Marques, L. P. Repizo et al., “De novo thrombotic microangiopathy after kidney transplantation: clinical features, treatment, and long-term patient and graft survival,” Transplantation Proceedings, vol. 44, no. 8, pp. 2388–2390, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group, “KDIGO clinical practice guideline for the care of kidney transplant recipients,” American Journal of Transplantation, vol. 9, no. 3, pp. S1–S157, 2009. View at Publisher · View at Google Scholar
  9. E. Rodrigo, M. A. De Cos, B. Sánchez et al., “High initial blood levels of tacrolimus in overweight renal transplant recipients,” Transplantation Proceedings, vol. 37, no. 3, pp. 1453-1454, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. P. A. Jacobson, D. Schladt, W. S. Oetting et al., “Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs,” American Journal of Transplantation, vol. 12, no. 12, pp. 3326–3336, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Stratta, M. Quaglia, T. Cena et al., “The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation,” European Journal of Clinical Pharmacology, vol. 68, no. 5, pp. 671–680, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Mihara, T. Mori, Y. Aisa et al., “Greater impact of oral fluconazole on drug interaction with intravenous calcineurin inhibitors as compared with intravenous fluconazole,” European Journal of Clinical Pharmacology, vol. 64, no. 1, pp. 89–91, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. N. Vavic, N. Rancic, V. Dragojevic-Simic et al., “The influence of comedication on tacrolimus blood concentration in patients subjected to kidney transplantation: a retrospective study,” European Journal of Drug Metabolism and Pharmacokinetics, vol. 39, no. 4, pp. 243–253, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Størset, N. Holford, K. Midtvedt, S. Bremer, S. Bergan, and A. Åsberg, “Importance of hematocrit for a tacrolimus target concentration strategy,” European Journal of Clinical Pharmacology, vol. 70, no. 1, pp. 65–77, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Krenzien, A. ElKhal, M. Quante et al., “A rationale for age-adapted immunosuppression in organ transplantation,” Transplantation, vol. 99, no. 11, pp. 2258–2268, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. Y.-Y. Shi, D. A. Hesselink, and T. van Gelder, “Pharmacokinetics and pharmacodynamics of immunosuppressive drugs in elderly kidney transplant recipients,” Transplantation Reviews, vol. 29, no. 4, pp. 224–230, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. J. George, K. Byth, and G. C. Farrell, “Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver,” Biochemical Pharmacology, vol. 50, no. 5, pp. 727–730, 1995. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Hod and A. S. Goldfarb-Rumyantzev, “Clinical issues in renal transplantation in the elderly,” Clinical Transplantation, vol. 29, no. 2, pp. 167–175, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. S. S. Han, D. H. Kim, S. M. Lee et al., “Pharmacokinetics of tacrolimus according to body composition in recipients of kidney transplants,” Kidney Research and Clinical Practice, vol. 31, no. 3, pp. 157–162, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. J. F. Trotter, J. C. Osborne, M. Heller, and U. Christians, “Effect of hepatitis C infection on tacrolimus doses and blood levels in liver transplantation recipients,” Alimentary Pharmacology & Therapeutics, vol. 22, no. 1, pp. 37–44, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Kugelmas, M. J. Osgood, J. F. Trotter et al., “Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection,” Liver Transplantation, vol. 9, no. 11, pp. 1159–1165, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Salm, P. J. Taylor, A. Clark et al., “High-performance liquid chromatography-tandem mass spectrometry as a reference for analysis of tacrolimus to assess two immunoassays in patients with liver and renal transplants,” Therapeutic Drug Monitoring, vol. 19, no. 6, pp. 694–700, 1997. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Grenda, S. Prokurat, A. Ciechanowicz, B. Piatosa, and P. Kaliciński, “Evaluation of the genetic background of standard-immunosuppressant-related toxicity in a cohort of 200 paediatric renal allograft recipients - A retrospective study,” Annals of Transplantation, vol. 14, no. 3, pp. 18–24, 2009. View at Google Scholar · View at Scopus
  24. N. Pallet, I. Etienne, M. Buchler et al., “Long-term clinical impact of adaptation of initial tacrolimus dosing to CYP3A5 genotype,” American Journal of Transplantation, vol. 16, no. 9, pp. 2670–2675, 2016. View at Publisher · View at Google Scholar · View at Scopus